These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 16924146)

  • 1. Antimicrobial activities of cinnamyl rifamycin derivatives, T-9 and T-11, against Mycobacterium tuberculosis and Mycobacterium avium complex (MAC) with special reference to the activities against intracellular MAC.
    Sato K; Shimizu T; Dimova V; Tomioka H
    Microbiol Immunol; 2006; 50(8):621-3. PubMed ID: 16924146
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antimicrobial activities of levofloxacin, clarithromycin, and KRM-1648 against Mycobacterium tuberculosis and Mycobacterium avium complex replicating within Mono Mac 6 human macrophage and A-549 type II alveolar cell lines.
    Sato K; Tomioka H; Akaki T; Kawahara S
    Int J Antimicrob Agents; 2000 Sep; 16(1):25-9. PubMed ID: 11185410
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [MICs and MBCs of levofloxacin, clarithromycin, and KRM-1648 for Mycobacterium tuberculosis and M. avium complex residing in MONO-MAC-6 human macrophage-like cell and A-549 human type II alveolar epithelial cell lines].
    Sato K; Ogasawara K; Akaki T; Tomioka H
    Kekkaku; 1999 Jul; 74(7):571-7. PubMed ID: 10481412
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antimicrobial activity of picolinic acid against extracellular and intracellular Mycobacterium avium complex and its combined activity with clarithromycin, rifampicin and fluoroquinolones.
    Cai S; Sato K; Shimizu T; Yamabe S; Hiraki M; Sano C; Tomioka H
    J Antimicrob Chemother; 2006 Jan; 57(1):85-93. PubMed ID: 16303883
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antimicrobial activities of benzoxazinorifamycin (KRM-1648) and clarithromycin against Mycobacterium avium-intracellulare complex within murine peritoneal macrophages, human macrophage-like cells and human alveolar epithelial cells.
    Sato K; Tomioka H
    J Antimicrob Chemother; 1999 Mar; 43(3):351-7. PubMed ID: 10223590
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intramacrophage passage of Mycobacterium tuberculosis and M. avium complex alters the drug susceptibilities of the organisms as determined by intracellular susceptibility testing using macrophages and type II alveolar epithelial cells.
    Tomioka H; Sato K; Sano C; Sano K; Shimizu T
    Antimicrob Agents Chemother; 2002 Feb; 46(2):519-21. PubMed ID: 11796367
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [In vitro antimicrobial activities of quinolones, rifamycins and macrolides against Mycobacterium tuberculosis and M.avium complex: attempt to establish new assay methods which accurately reflect therapeutic effects of test agents in vivo].
    Sato K; Tomioka H
    Kekkaku; 1999 Jan; 74(1):63-70. PubMed ID: 10067057
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [In vitro activities of new rifamycin derivatives against Mycobacterium tuberculosis and M. avium complex].
    Yamamoto T; Amitani R; Kuze F; Suzuki K
    Kekkaku; 1990 Dec; 65(12):805-10. PubMed ID: 2127615
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prospects for development of new antimycobacterial drugs.
    Tomioka H
    J Infect Chemother; 2000 Mar; 6(1):8-20. PubMed ID: 11810525
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro antimycobacterial activity of newly synthesised S-alkylisothiosemicarbazone derivatives and synergistic interactions in combination with rifamycins against Mycobacterium avium.
    De Logu A; Saddi M; Onnis V; Sanna C; Congiu C; Borgna R; Cocco MT
    Int J Antimicrob Agents; 2005 Jul; 26(1):28-32. PubMed ID: 15955675
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative in vitro and in vivo activity of rifabutin and rifampicin against Mycobacterium avium complex.
    Saito H; Sato K; Tomioka H
    Tubercle; 1988 Sep; 69(3):187-92. PubMed ID: 2855458
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prospects for development of new antimycobacterial drugs, with special reference to a new benzoxazinorifamycin, KRM-1648.
    Tomioka H
    Arch Immunol Ther Exp (Warsz); 2000; 48(3):183-8. PubMed ID: 10912623
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro activity of new rifamycins against rifampicin-resistant M. tuberculosis and MAIS-complex mycobacteria.
    Dickinson JM; Mitchison DA
    Tubercle; 1987 Sep; 68(3):177-82. PubMed ID: 2834842
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activities of the benzoxazinorifamycin KRM 1648 and ethambutol against Mycobacterium avium complex in vitro and in macrophages.
    Inderlied CB; Barbara-Burnham L; Wu M; Young LS; Bermudez LE
    Antimicrob Agents Chemother; 1994 Aug; 38(8):1838-43. PubMed ID: 7986017
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Prospects for development of new antituberculous drugs].
    Tomioka H
    Kekkaku; 2002 Aug; 77(8):573-84. PubMed ID: 12235850
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Study of the minimal inhibitory concentration of rifabutine (Ansamycin LM 427) for Mycobacterium tuberculosis, Mycobacterium xenopi and Mycobacterium avium-intracellulare].
    Truffot-Pernot C; Giroir AM; Maury L; Grosset J
    Rev Mal Respir; 1988; 5(4):401-6. PubMed ID: 2845531
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro activities against mycobacteria of two long-acting rifamycins, FCE22807 and CGP40/469A (SPA-S-565).
    Dickinson JM; Mitchison DA
    Tubercle; 1990 Jun; 71(2):109-15. PubMed ID: 2120827
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antimicrobial activities of clarithromycin, gatifloxacin and sitafloxacin, in combination with various antimycobacterial drugs against extracellular and intramacrophage Mycobacterium avium complex.
    Tomioka H; Sano C; Sato K; Shimizu T
    Int J Antimicrob Agents; 2002 Feb; 19(2):139-45. PubMed ID: 11850167
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activity of KRM 1648 or rifabutin alone or in combination with clarithromycin against Mycobacterium avium complex in human alveolar macrophages.
    Suzuki K; Tsuyuguchi K; Matsumoto H; Yamamoto T; Hashimoto T; Tanaka E; Amitani R; Kuze F
    Int J Tuberc Lung Dis; 1997 Oct; 1(5):460-7. PubMed ID: 9441102
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New rifabutin analogs: synthesis and biological activity against Mycobacterium tuberculosis.
    Barluenga J; Aznar F; García AB; Cabal MP; Palacios JJ; Menéndez MA
    Bioorg Med Chem Lett; 2006 Nov; 16(22):5717-22. PubMed ID: 16987658
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.